Study2020

[Effects of Oral Magnesium and Antacid Administration on Serum Magnesium Levels and Renal Function in Patients Receiving Cisplatin]

Kamo Y, Sato J, Tanaka R, Shino M

Gan to kagaku ryoho. Cancer & chemotherapy · 0 citations

Review labels

Funding not disclosed

Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.

How it was studied

Design
Cohort study (classified by our AI screen)
Studied in
People
Main outcome
Health markers and function

Who paid for it

Funding
Funding not disclosed

Publication

Published
2020-04-01 · Gan To Kagaku Ryoho · vol. 47 · issue 4 · pp. 605–608
Publisher
National Institutes of Health
Cited
0 citations · more than 5% of similar papers · 0.0× the field average
References
0 works
Access
Paywalled
Research areas
Magnesium in Health and Disease
Keywords
Hypomagnesemia, Antacid, Medicine, Renal function, Magnesium, Oral administration, Internal medicine, Cisplatin, Gastroenterology, Pharmacology, Chemotherapy, Chemistry
MeSH
humans, cisplatin, magnesium, magnesium oxide, antacids, administration, oral, retrospective studies

4 authors

From JP

  • Yoshiko KamoShizuoka Cancer Center
  • Junya Sato
  • Rei Tanaka
  • Michihiro Shino

Abstract

The efficacy of magnesium oxide(MgO)when taken daily as a laxative for hypomagnesemia and renal dysfunction due to cisplatin(CDDP)administration is not clear. It is known that the efficacy of MgO is suppressed when used in combination with antacids, such as proton pump inhibitors. Therefore, we conducted a retrospective analysis of the effects of MgO and antacid administration on serum Mg levels and renal function(estimated glomerular filtration rate: eGFR)in CDDP-treated patients. In the analysis of up to 6 cycles of CDDP administration, the serum Mg levels and eGFR of CDDP-treated patients (n=614)were significantly reduced(p<0.001 and p=0.002, respectively, ANOVA). Patients who used MgO had higher serum Mg levels than patients who did not use MgO(p<0.001, ANOVA). However, no effect of MgO administration was observed on eGFR(p=0.832, ANOVA). There was no effect of antacid combination on serum Mg levels and eGFR in patients receiving MgO. MgO use may have contributed to a reduction in hypomagnesemia. However, it was considered that the decrease in eGFR could not be suppressed as the improvement in hypomagnesemia was slight. Intravenous Mg supplementation is required when CDDP is administered. Furthermore, it is expected that oral Mg supplementation will improve Mg absorption.

Abstract via Europe PMC. Copyright remains with the authors or publisher.

Community trust

Loading…

How much do you trust this study's findings?

0 · not at all10 · completely

Comments

Sign in to rate, comment on or flag this study.Sign in

Something wrong here?

Flag this study if its information, labels or funding look wrong. An editor reviews every flag.

Sign in to rate, comment on or flag this study.Sign in

Educational information about published research. Not medical advice, and not a recommendation to start or stop anything.